Candid inks three T cell engager deals; PepGen trial put on hold

Plus, news about Foghorn Ther­a­peu­tics, In­cyte, BioN­Tech, Gal­der­ma, Basilea, In­novia, Pharm­ing, bit.bio, Promise Bio, Out­look Ther­a­peu­tics and Tre­vi Ther­a­peu­tics:

Can­did Ther­a­peu­tics’ trio of T cell …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.